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Tracer studies suggest that phospholipid DHA (PL-DHA) more effectively targets the brain than triglyceride DHA (TAG-DHA), although the mechanism and
whether this translates into higher brain DHA concentrations are not clear. Rats were gavaged with [U-3H]PL-DHA and [U-3H]TAG-DHA and blood sampled over
6 h prior to collection of brain regions and other tissues. In another experiment, rats were supplemented for 4 weeks with TAG-DHA (fish oil), PL-DHA (roe PL)
or a mixture of both for comparison to a low-omega-3 diet. Brain regions and other tissues were collected, and blood was sampled weekly. DHA accretion rates
were estimated using the balance method. [U-3H]PL-DHA rats had higher radioactivity in cerebellum, hippocampus and remainder of brain, with no differences
in other tissues despite higher serum lipid radioactivity in [U-3H]TAG-DHA rats. TAG-DHA, PL-DHA or a mixture were equally effective at increasing brain DHA.
There were no differences between DHA-supplemented groups in brain region, whole-body, or tissue DHA accretion rates except heart and serum TAG where the
PL-DHA/TAG-DHA blend was higher than TAG-DHA. Apparent DHA β-oxidation was not different between DHA-supplemented groups. This indicates that more
labeled DHA enters the brain when consumed as PL; however, this may not translate into higher brain DHA concentrations.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Docosahexaenoic acid; Brain; Triacylglycerol; Phospholipid; Serum; Uptake1. Introduction
Docosahexaenoic acid (DHA, 22:6n-3) is highly concentrated in the
brain where it composes approximately 10% of all fatty acids [1]. DHA
regulatesmanyneurological processes includingneuronal survival [2],
synaptogenesis [3], neuronal plasticity [4] and neuroinﬂammation [5].
Experimental depletion of brain DHA in animal studies is associated
with behavioral impairments [reviewed in [6]], and some neurode-
generative and neuropsychiatric disorders have been associated with
low brain DHA content. For example, lower postmortem brain DHA in
select brain regions and lipid classes has been found in patients with☆ This work was funded by Arctic Nutrition AS, NO-6155 Ørsta, Norway.
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[13,14], bipolar disorder [15] and schizophrenia [16], although some
studies show no differences [1,17–19]. This has led the ﬁeld to
speculate that strategies to increase brain DHA concentration may be
effective in treatment/prevention of neurodegenerative/neuropsychi-
atric disorders, assuming that low brain DHA is causally linked to the
disease progression [20–23].
The brain can synthesize DHA fromα-linolenic acid (ALA, 18:3n-3)
[24,25]; however, the synthesis rate (1.5 nmol/g/d) [24] is much
lower than the total rate of brainDHAaccretion (190 nmol/g/d) [26] in
rats, indicating that uptake from serum DHA is likely the main source
of DHA for the brain [24]. The plasma lipid pool from which the brain
takes up DHA is not agreed upon; however, there is evidence that
plasma unesteriﬁed DHA is themajor contributor [25,27,28], although
other pools may contribute, such as lysophosphatidylcholine [29,30].
Dietary interventions that target serum lipid pools important for brain
DHA uptake may be effective in targeting brain DHA.
Dietary DHA is typically esteriﬁed to TAG, although supplements
with a high proportion of DHA esteriﬁed to phospholipids (PL), such as
krill oils and ﬁsh roe phospholipid extracts, are increasingly common.
Several studies have attempted to compare the bioavailability of TAG-
or PL-enriched sources of DHA based on responses of blood
biomarkers and have concluded either higher bioavailability of PL-he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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controversial [38–41].
There is also some evidence that dietary PL-DHAmay target the brain
more effectively than TAG-DHA. Liu et al. orally administered [U-13C]DHA
esteriﬁed in the sn-2 position of TAG or PC to neonatal piglets and found
approximately twofold greater labeled DHA in gray matter and
synaptosomes [42] of [U-13C]DHA-PC gavaged piglets. Similarly, Graf
et al. orally administered [1-14C]DHA esteriﬁed to sn-2 of PC and TAG and
found higher radioactivity in brain regions of 10-week-old rats gavaged
with [1-14C]DHA-PC, but not in 2- or 4-week-old rats [43].
Taken together, it appears that dietary PL-DHA may more
effectively target the brain relative to TAG-DHA; however, it is not
known if this translates into higher brainDHA concentration following
supplementationwith a source of PL-DHA comparedwith TAG-DHA. It
is possible that ingested PL-DHA may more effectively enrich serum
lipid pools that target brain DHA compared with TAG-DHA, as there is
some evidence that dietary PL and TAG target different serum lipid
pools upon digestion and absorption [44,45]. However, a detailed
time-course comparing the serum lipid class enrichment following
ingestion of DHA-containing PL and TAG tracers has not been
performed, nor has it been assessed whether acute postprandial
serum lipid class enrichment kinetics translate into differences in
serum lipid class DHA concentration in response to semichronic PL- or
TAG-DHA supplementation.
Therefore, the goal of this study was to examine whether the
higher brain tracer uptake of ingested PL-DHA compared to TAG-DHA
translated into higher brain DHA content following 4 weeks of
supplementation with a source of PL-DHA, TAG-DHA or a mixture of
the two. In addition, differences in serum lipid pool enrichment
following ingestion of PL-DHA and TAG-DHA tracer were character-
ized and compared to changes in serum lipid pool DHA concentration
following dietary PL-DHA vs. TAG-DHA supplementation. Differences
in other tissues were also assessed.
2. Material and methods
2.1. Radiotracer gavage study — tracers
Sn-1,3-dpalmitoyl-2-docosahexaenoylglycerol (TAG-DHA) and 1-palmitoyl-2-doc-
osahexaenoyl-sn-glycero-3-phosphocholine (DHA-PC) were purchased from Avanti
Polar Lipids (Alabaster, AL, USA) and were uniformly labeled with 3H by Moravek
Biochemicals (Brea, CA, USA) to form [U-3H]TAG-DHA [U-3H]DHA-PC, respectively.
Radiochemical purity of the tracerswas N99.8% as determined byMoravek Biochemicals
and the speciﬁc activity of tracers was 1.1 mCi/mmol for [U-3H]TAG-DHA and 1.6 mCi/
mmol for [U-3H]DHA-PC. Tracers were shipped and dissolved in toluene and, prior to
use, were dissolved in olive oil (Sigma-Aldrich, St. Louis, MO, USA) following
evaporation of toluene under a stream of N2. The tracer was dissolved to a ﬁnal
concentration of 500 μCi/ml for [U-3H]TAG-DHA and 300 μCi of [U-3H]DHA-PC.
Different tracer concentrations were due to availability of material.
2.2. Radiotracer gavage study — animals and diets
All procedures performed on animals were approved by the University of Toronto
Animal Care Committee in accordance with guidelines set by the Canadian Council of
Animal Care. Animals were housed with ad libitum access to food and water with a
12:12-h light:dark cycle and controlled temperature of 22±1 °C.
Male Long–Evans rats arrived at the University of Toronto animal care facility at
10 days of age with lactating dams. Dams were immediately placed on a low omega-3
diet with 0.14±0.01% of fatty acids as n-3 PUFA (Dyet's Inc., Bethlehem Pennsylvania)
modiﬁed from theAIN-93G formulation [46] as shown in Table 1. ALA content of the diet
was consistent with previous work [46]. Pups were weaned onto the same diet at
21 days of age. Pups were maintained on this diet until 11 weeks of age when they
underwent carotid artery cannulation. Brieﬂy, rats were anesthetized through
isoﬂurane inhalation (5% induction, 1–2.5% maintenance) followed by subcutaneous
injection of ketoprofen (5 mg/kg; Merial Canada Inc., Baie d'Urfé, QC, Canada), and
incision sites (scapular, superior thoracic) were shaved and disinfected. Carotid artery
was isolated by blunt dissection and cannulated with sterile polyethylene catheter (PE
50, Intramedic™; Becton Dickinson, Franklin Lakes, NJ, USA) tipped with 1.5 cm of
silicone tubing (silicone tubing 0.020 in. inner diameter and 0.037 in. outer diameter,
VWR; Mississauga, ON, Canada). The cannula was externalized in the scapular region
and a skin button (Braintree Scientiﬁc, Braintree, MA, USA) was sutured to facilitate
assembly of the sampling system.After a 24-h recovery from surgery, a 250-μl baseline blood sample was taken
followed by ﬂushing the line with 1% heparinized saline to ensure line patency
throughout the experiment. Rats were then gavaged with 500 μl of one of the two
tracers (n=4 for TAG-DHA, n=5 for PC-DHA) dissolved in olive oil providing 454.5 and
192.5 mmol of the [U-3H]TAG-DHA (500 μCi) and [U-3H]DHA-PC (308 μCi), respec-
tively. The rat was then tethered to a counterbalanced sampling system (Instech
Laboratories, Plymouth Meeting, PA, USA). Blood samples (250 μl) were taken 30, 60,
90, 120, 150, 180, 210, 240, 270, 300, 330 and 360 min postgavage. In the event of
difﬁculty obtaining blood draw from the cannula, a tail-vein blood drawwas performed.
Blood was centrifuged at 10,000 g for isolation of serum and immediately frozen at−
80 °C until analysis. Rats were euthanized by lethal injection of T-61 (embutramide
200 mg/ml, mebezodium iodide 50 mg/ml, tetrocaine hydrochloride 5 mg/ml admin-
istered at 300-μl/kg body weight, Merck Animal Health, Kirkland, QUE, Canada) via the
carotid catheter 360 min postgavage, and brain regions (cortex, cerebellum, hippo-
campus, striatum, brainstem and rest of brain) as well as liver, perirenal adipose tissue,
heart, small intestine (5 cm inferior to pyloric sphincter) and abdominal skin were
collected, rinsed in saline and frozen at−80 °C until analysis.
2.3. Radiotracer gavage study — lipid analysis
Lipids were extracted from serum and tissues by the method of Folch, Lees and
Sloane Stanley [47] using 2:1:0.8 chloroform:methanol:0.88% KCl (v/v/v) as previously
described [48,49]. Thin-layer chromatography was used to isolate brain region PL as
well as to collect lipid classes in serum and liver (PL, monoacylglycerols, co-eluting
diacylglycerols/cholesterol, nonesteriﬁed fatty acids, TAGs, cholesteryl esters) using
silica G plates (silica gel 60, EMD Millipore, MA, USA) and a mobile phase of 60:40:2
heptane:diethyl ether:glacial acetic acid (v/v/v). Lipid classes were visualized by
spraying resolved plates with 0.1% (w/v) 8-anilino-1-naphthalenesulfonic acid and
identiﬁed in relation tomobility of a reference standardmixture containing lipid classes
of interest. Only total lipid extracts of heart, adipose, skin and intestine were analyzed.
Radioactivity of total lipid extracts and lipid fractions was measured on a Hewlett-
Packard Tri-Carb 2900TR Liquid Scintillation Analyzer with detector efﬁciency of
45.81%. Radioactive data were normalized to percentage of gavaged dose. Unidirec-
tional incorporation coefﬁcients were also determined [50] using the average area
under the curve for radioactivity in unesteriﬁed fatty acids, esteriﬁed fatty acids and
total serum lipid radioactivity according to the following equation
ki ¼





Where C⁎i(T) is the radioactivity of brain region i at the end of the experiment, and
∫0TC⁎sdt is the area under the curve of the serum radioactivity of serum lipid i. k* was
calculated for unesteriﬁed fatty acids, esteriﬁed lipids and total lipid radioactivity.
2.4. PL vs. TAG-DHA supplementation study — animals and diets
Ten-day-old male Long–Evans rat pups with lactating dams arrived at the
University of Toronto animal care facility, and the dams were immediately placed on
a lown-3 PUFAdiet (same as used in radiotracer study), andpupswereweaned onto the
low n-3 PUFA diet at 21 days of age. At 11 weeks of age, one group of rats was sacriﬁced
by high-energy head-focused microwave ﬁxation (13.5 kW for 1.6 s; Cober Electronics
Inc., Stratford, CT, USA [48,49,51]) following collection of tail vein blood, and brain
regions (as in radiotracer study), liver, heart, adipose, small intestine, skin and perirenal
adipose were collected to estimate baseline DHA concentrations (n=8). The rest of the
rats were randomized to one of four experimental diets: (a) a low n-3 PUFA diet
supplemented with olive oil (OO diet; n=8); (b) a diet supplemented with ﬁsh oil (FO
diet; n=8); (c) a diet supplementedwith herring caviar phospholipid concentrate (PLC
diet; n=8) with 81% of DHA esteriﬁed to phospholipids; or (d) a diet supplemented
with a blend of FO and PLC (FO+PLC diet; n=7) with 30% of the DHA esteriﬁed to
phospholipids (lipid class composition analysis performed by Mylneﬁeld, Dundee,
Scotland). Oil sources and fatty acid concentration of diets are shown in Table 1. DHA-
containing oils were prepared by Arctic Nutrition (fatty acid composition in
Supplemental Table 1). All DHA-supplemented diets (FO, PLC, FO+PLC) were
formulated such that DHA would comprise 2% of total fatty acid mass, as this has
been suggested to be the dietary DHA content at which brain DHA is maximal [52]. Rats
were maintained on experimental diets for 4 weeks (from postnatal week 11 to week
15) with body weight, 24-h food intake and serum DHA (sampled via tail vein)
measured weekly. At the conclusion of supplementation, blood was sampled from the
tail vein, and rats were killed by high-energy head-focused microwave ﬁxation, and
samples were collected identically to baseline rats. Carcasses and 24-h fecal samples
were also collected and stored at−80 °C.
2.5. PL-DHA vs. TAG-DHA supplementation study — lipid analysis
Lipids were extracted from serum, tissues and feces as described for the radiotracer
study. Carcasseswere homogenized in aWaring industrial blender (model CB15)with a
4-L stainless steel pitcher (Hendrix Restaurant Equipment and Supplies, Brockville, ON,
USA) with water to facilitate homogenization, and lipids were extracted in duplicate.
For all samples, an internal standard was added prior to lipid extraction for
Table 1
Fat source and fatty acid composition of rodent diets
Name Low n-3 PUFA Olive oil Fish oil Phospholipid concentrate Fish oil + phospholipid concentrate
Fat source g/kg diet
Hydrogenated coconut oil 66.2 50.0 50.0 50.0 50.0
Safﬂower oil 33.8 33.8 33.8 33.8 33.8
Olive oil 0 16.2 8.8 3.4 7.85
Fish oil 0 0 7.4 0 0
Phospholipid concentrate 0 0 0 12.8 0
Phospholipid concentrate + ﬁsh oil 0 0 0 0 8.35
Total 100 100 100 100 100
Fatty acid % composition1
C 10:0 4.44±0.54 2.36±0.45 2.32±0.25 2.38±0.08 2.35±0.11
C 12:0 37.45±0.98 25.94±0.51 26.5±0.45 27.57±0.11 27.14±0.2
C 14:0 14.21±0.47 10.27±0.12 10.98±0.12 11.47±0.08 11.12±0.12
C 16:0 8.90±0.23 9.96±0.19 9.62±0.06 10.58±0.14 9.85±0.04
C 18:0 7.38±0.18 6.59±0.17 6.77±0.12 7.08±0.1 6.82±0.06
C 20:0 0.17±0.01 0.22±0.005 0.23±0.01 0.2±0.01 0.22±0.001
SFA 75.11±0.56 55.78±1.07 56.64±0.69 59.53±0.23 57.69±0.45
C 16:1 0.06±0.01 0.35±0.01 0.47±0.004 0.49±0.001 0.4±0.003
C 18:1n-7 0.19±0.01 0.68±0.03 0.58±0.02 0.61±0.01 0.57±0.01
C 18:1n-9 5.25±0.15 16.55±0.39 12.25±0.21 9.64±0.07 11.72±0.15
C 20:1n-9 0.06±0.0001 0.1±0.01 0.34±0.01 0.19±0.004 0.15±0.01
C 22:1n-9 0.10±0.01 0.09±0.001 0.1±0.005 0.09±0.01 0.09±0.004
C 24:1n-9 TR 0.03±0.005 0.13±0.005 0.09±0.01 0.11±0.003
MUFA 5.7±0.17 17.79±0.41 13.87±0.25 11.14±0.07 13.06±0.14
C 18:2n-6 18.9±0.36 26.09±0.67 25.87±0.4 25.88±0.2 25.76±0.32
C 20:4n-6 TR TR TR TR TR
C 22:4n-6 0.1±0.01 0.05±0.013 0.08±0.01 0.04±0.01 0.06±0.01
N-6 19.05±0.38 26.18±0.66 26.08±0.39 26.02±0.2 25.94±0.33
C 18:3n-3 0.08±0.003 0.19±0.01 0.18±0.003 0.19±0.002 0.17±0.004
C 20:5n-3 TR TR 0.75±0.014 0.91±0.02 0.71±0.012
C 22:5n-3 TR TR 0.23±0.004 0.07±0.001 0.17±0.003
C 22:6n-3 0.05±0.002 0.05±0.002 2.24±0.04 2.12±0.04 2.25±0.04
N-3 0.14±0.01 0.25±0.01 3.41±0.05 3.31±0.04 3.31±0.06
PUFA 19.19±0.39 26.43±0.66 29.49±0.44 29.33±0.2 29.25±0.32
N-6/N-3 135.1±3.35 104.31±0.61 7.65±0.05 7.86±0.12 7.83±0.19
TR: trace (b0.05% of fatty acids), SFA: saturated fatty acids, MUFA: monounsaturated fatty acids, PUFA: polyunsaturated fatty acids.
1 Data are mean ± SD from triplicate analysis in our laboratory. Levels of 14:1, 18:3n-6, 20:2n-6, 20:4n-6, 22:4n-6, 22:5n-6 were measured and found to be negligible (b0.05% of
fatty acids).
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TAGs (triheptadecanoate, Nuchek Prep) unesteriﬁed fatty acids (heptadecanoic acid,
Nuchek Prep) or cholesteryl esters (cholesteryl heptadecanoate, Nuchek Prep). Neutral
lipid classes were isolated from serum lipid extracts by TLC as described for the
radiotracer study. Lysophosphatidylcholine was isolated by TLC on silica H plates
(Analtech, Newark, DE, USA) with a mobile phase of chloroform:methanol:acetic
acid:acetone: water (40:25:7:4:2 by vol) [53]. Fatty acid methyl esters (FAMEs) were
prepared by heating at 100 °C for 1 h in 14% boron triﬂouride in methanol [54].
2.6. PL-DHA vs. TAG-DHA supplementation study — gas chromatography
FAMEs were resolved on a Varian 430 gas chromatograph- FID (Varian, Lake Forest,
CA, USA) with a DB-23 capillary column (30 m×0.25 mm interior diameter × 0.25-μm
ﬁlm thickness; Agilent Technologies, Mississauga, ON, USA) with 1-ul injection volume
running in splitlessmode. Gas chromatography conditionswere as previously described
[48,55]. Brieﬂy, injector and detector ports were 250 °C, temperature program was
50 °C for 2 min, increasing at 20 °C/min, and held at 170 °C for 1 min, then increased at
3 °C/min and held at 212 °C for 5 min to complete the run at 32 min with helium as
carrier gas with ﬂow rate of 0.7 ml/min. Peaks were identiﬁed in relation to a reference
standard mixture (GLC 455 mixed with GLC-48 and supplemented with 8:0, 10:0, and
12:0 FAMEs, Nuchek Prep). Concentrations of fatty acids were determined in relation to
peak area of internal standard.
2.7. PL-DHA vs. TAG-DHA supplementation study — calculations
The balance method [48,56–58] was used to determine brain region, tissue and
whole-body net DHA accretion rates using the following calculation:
DHA daily accretion rate ¼ DHA½ at beginning of study  DHA½ at end of study
number of days of supplementation
ð2ÞWhole-bodyapparentDHAβ-oxidation ratesweredeterminedusing the following calculation:
Apparent daily β  oxidation rate
¼ Dietary DHA consumed  whole body DHA accretion  fecal DHA excretionð Þ
number of days of supplementation
ð3Þ
2.8. Statistics
Statistical analysis was performed using SPSS Statistics Version 22 and Prism Version
4. Signiﬁcance was inferred at Pb .05. Comparison of tissue radioactivity between
[U-3H]TAG-DHAand [U-3H]PL-DHAwasdoneby independent samples t test. The effects of
time and tracer on serum lipid class radioactivity were assessed by two-way ANOVAwith
unweightedmeans analysiswith comparisons between tracers at each time point doneby
independent samples t test.Mean areaunder the curvewas also assessed for each tracer in
each serum lipid class. Comparison of tissue fatty acid concentrations between groups in
PL-DHA versus TAG-DHA supplementation study was done by one-way ANOVA with
Tukey's post-hoc test. Longitudinal changes in DHA concentration in serum lipid classes
were expressed relative to OO-fed rat within each week. Effects of all diets within each
week of supplementation were assessed by one-way ANOVA with Tukey's post-hoc test.
The effects of the different FO, PLC and FO+PLC and time were assessed in longitudinal
serum DHA concentration data by two-way ANOVA.
3. Results
3.1. Radiotracer study
Total radioactivity in the brain 6 h after oral gavage ofwas less than
2×10−5% of the gavaged dose for both tracers. Rats gavaged with
[U-3H]PC-DHAhad a signiﬁcantly greater proportionof the radiotracer
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postgavage as compared with rats gavaged with [U-3H]TAG-DHA
(78%, 140% and 69% higher, respectively) with no signiﬁcant
differences in cortex, striatum and brainstem (Fig. 1). Unidirectional
incorporation coefﬁcients for tracer uptake from serumwere higher in
cerebellum, hippocampus and remainder of brain of [U-3H]PC-DHA
compared with [U-3H]TAG-DHA rats with no differences in other
regions regardless of serum lipid pool examined (data not shown). No
signiﬁcant differences in radioactivity were observed in heart, liver,
skin or adipose between [U-3H]TAG-DHA and [U-3H]PC-DHA, al-
though there were differences in the distribution of radioactivity
among liver lipid classes (Supplementary Fig. 1).
Ingestion of both [U-3H]TAG-DHA and [U-3H]PC-DHA-labeled
serum lipid pools in the rank order TAG N diacylglycerol/cholesterol
N nonesteriﬁed fatty acids (NEFA) N PL N monoacylglycerols =
cholesteryl esters (CE). Radioactivity in all fractions appeared to
have plateaued or decreased by the end of the study (Fig. 2). The
highest labeling was observed for serum TAG in the [U-3H]TAG-DHA
gavaged animals at 5-h post gavage with 0.126% of the gavaged dose/
ml of serum. The pattern of labeling of serum lipid pools was different
between [U-3H]TAG-DHA and [U-3H]PC-DHA, as two-way ANOVA
revealed a signiﬁcant effect of tracer in the labeling of all serum lipids
pools examined except for total PL (Fig. 2). [U-3H]TAG-DHA tended to
have higher maximum labeling, reach the maximum labeling faster
and maintain a higher value of radioactivity longer compared with
[U-3H]PC-DHA in diacylglycerol/cholesterol, NEFA, monoacylglycerol
and in particular TAG. In contrast, [U-3H]PC-DHA had higher labeling
of CE.
3.2. PL-DHA versus TAG-DHA supplementation study
No differences in body weight or food intake between the dietary
groups were observed over the course of the study (Supplemental Fig.
2). Body weight was 566±53 g at the beginning of supplementation
and 625±64 g at the end of the 4-week supplementation period with
a signiﬁcant main effect of time but not of diet. Food intake was 31±
5 g/d at the beginning of supplementation and 29±4 g/d at the end of
the studywith no changes over time and no differences between diets.
Effects of experimental diets on brain region DHA is shown in Fig. 3
(full brain region fatty acid composition can be found in Supplemental
Tables 2–7). After 4 weeks of supplementation, rats in the DHA-free
OO supplemented group had brain region total lipid DHA concentra-Fig. 1. Percent of gavaged radioactivity recovered in total phospholipids of brain regions
6 h after gavage of [U-3H]TAG-DHA and [U-3H]PC-DHA. Signiﬁcantly higher enrichment
was found in remainder of brain, cerebellum and hippocampus in rats gavaged with
[U-3H]PC-DHA compared with [U-3H]TAG-DHA. Less than 2×10–5 of the dose was
recovered in total brain phospholipids. Data are mean ± S.E.M. of 4–5/group. *:
signiﬁcantly different from [U-3H]TAG-DHA gavaged rats by independent samples t test
(Pb .05).tions of 9.9, 10.1, 10.6, 11.1, 13.4 and 13.7 μmol/g in cortex, remainder
of brain, cerebellum, brainstem, hippocampus and striatum, respec-
tively. Supplementation with 2% of dietary fatty acids as DHA in FO,
PLC or FO+PLC resulted in signiﬁcantly higher brain DHA concentra-
tions compared with OO-fed controls (30–33% higher in cortex, 35–
43% higher in cerebellum, 27–31% higher in hippocampus, 28–32%
higher in brainstem and 26–35% higher in remainder of brain)with no
signiﬁcant differences in brain DHA concentration between the three
DHA-supplemented groups (Fig. 3). Striatum DHA concentrations
were not signiﬁcantly different between groups (P=.053).
The changes in fasting serum lipid class DHA concentrations in
response to DHA supplementation are shown in Fig. 4 (full serum lipid
class fatty acid compositions at conclusion of study are shown in
Supplemental Tables 8–11). All sources of DHA signiﬁcantly increased
all serum lipid DHA concentrations over the course of the study (time
Pb .0001 for all lipid classes). The largest increase in DHA concentra-
tion was found in serum triglycerides, with DHA supplementation
raising DHA concentration by 20–50-fold, with other fractions
increasing 3–15-fold. DHA-supplemented rats generally had higher
serum DHA compared to OO controls based on within-week ANOVA
analysis. In two-way ANOVA examining different DHA-containing
diets relative to OO-control, a signiﬁcant main effect of DHA
supplementation diet was found only for serum unesteriﬁed fatty
acids (P=.0051), in which FO-fed rats had higher DHA at 3 weeks of
supplementation compared with PLC (FO+PLC was intermediate),
while all groups were signiﬁcantly higher than control. The only other
instance of signiﬁcant differences between DHA-supplemented rats
was in serum TAG after 4 weeks of supplementation, in which
FO+PLC was signiﬁcantly higher than FO.
Effects of diets on liver, heart, adipose, intestine and skin DHA
concentration is shown in Fig. 5 (full fatty acid compositions reported
in Supplemental Tables 12–16). Supplementationwith DHA increased
total lipid DHA concentration by between 7 and 10 fold in liver, heart,
small intestine and skin, while an increase of only three- to fourfold
was found in adipose tissue (Pb .05 for all relative to OO). All DHA-
supplemented diets were equally effective at increasing tissue total
lipid DHA concentrations in all tissues except for the heart, in which
the FO+PLC-fed rats had 27% higher heart DHA comparedwith FO-fed
rats, with PLC being intermediate.
The results of the DHA balance analysis are summarized in Table 2.
Brain region accretion rates were higher in FO, PLC and FO+PLC rats
compared to OO controls and were not different between DHA-
supplemented groups. Whole body DHA was approximately 10-fold
higher in DHA-supplemented groups comparedwith OO controlswith
no differences between DHA sources, resulting in no differences in the
whole body accretion rates. The apparent daily DHA oxidation rate
was highest in FO+PLC-fed rats compared with PLC-fed rats, with FO-
fed being intermediate (all DHA-supplemented groups were higher
than the OO control group), although all DHA-fed groups had similar
proportions of dietary DHA that was apparently β-oxidized, ranging
from 84 to 88% of ingested DHA. Among DHA-fed rats, the fecal DHA
excretion was highest in PLC-fed rats compared with FO and FO+PLC
rats, while all DHA-fed rats had higher fecal DHA excretion compared
with OO-fed controls. The percentage of dietary DHA excreted in feces
was higher in PLC-fed rats compared with FO and FO+PLC and was
less than 0.5% of dietary DHA in all groups.
4. Discussion
Numerous groups have developed approaches to target the brain
with DHA [42,59–61]; however, whether dietary strategies can also
increase DHA supply to the brain is not clear. Ingestion of PL-DHA has
been suggested to increase bloodDHAmore effectively comparedwith
TAG-DHA [31–33], and previous studies have shown higher brain
uptake of labeled DHA following ingestion of PL-DHA tracers as
Fig. 2. Percent of gavaged dose recovered in serum lipid classes over 6 h following gavage of [U-3H]TAG-DHA and [U-3H]PC-DHA. Radioactivity of all lipid classes increased during the
experiment, and DHA ester was a signiﬁcant factor in all lipid classes except serum phospholipids. [U-3H]TAG-DHA had higher radioactivity in TAG, unesteriﬁed fatty acids,
monoacylglycerols, and diacylglycerol/cholesterol while [U-3H]PC-DHA had higher radioactivity in serum cholesteryl esters. Data is mean± S.E.M. of three to ﬁve/time-point/group. *:
signiﬁcantly different at indicated time point by independent samples t test (Pb .05). AUC: average area under the curve.
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differences in the acute brain tracer levels and serum lipid pool
enrichment following ingestion of [U-3H]PC-DHA and [U-3H]TAG-
DHA and compared this to the effects of dietary supplementationwith
sources of TAG-DHA, PL-DHA or a mixture of both. Similar to previous
studies [42,43], we show that a higher percentage of ingested
[U-3H]PC-DHA radioactivity was found in brain lipids compared
with [U-3H]TAG-DHA. This effect appears to be speciﬁc to thebrain, as no signiﬁcant differences in radiotracer enrichment were
found in other tissues examined in general agreement with previous
work [43]. However, the higher brain radiotracer uptake in [U-3H]PC-
DHA gavage did not translate into higher brain DHA concentrations in
PL-DHA fed rats compared with TAG-DHA in the 4-week PL-DHA
versus TAG-DHA supplementation study. This indicates that while
ingestion of DHA esteriﬁed to PL may increase delivery of DHA to
brain lipids postprandially, this may not necessarily translate into
Fig. 3. DHA concentration of brain regions from rats fed diets supplemented with olive oil, ﬁsh oil, ﬁsh roe phospholipid concentrate or a mixture of ﬁsh oil and ﬁsh roe phospholipid
concentrate. All groups supplemented with DHA had higher brain DHA compared with the olive oil control group and were not different from each other. The only exception was
striatum, in which there was no signiﬁcant effect of diet on brain DHA concentration. Data aremean± S.E.M. for seven to eight/group. Bars with a different superscript are signiﬁcantly
different by Tukey's post-hoc test following one-way ANOVA (Pb .05). OO: olive oil, FO: ﬁsh oil, PLC: phospholipid concentrate, FO+PLC: ﬁsh oil + phospholipid concentrate.
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dietary intervention.
There are several possible explanations for the apparent lack of
agreement between the tracer and supplementation experiments. The
DHA supplementation diets used contained 2% of fatty acids as DHA,
which has previously been suggested to be the dietary DHA content at
which brain DHA is maximal [52]. The time-course of DHA repletion
using these diets has not been investigated; however, it is possible that
brain DHA had reached maximal concentration in all DHA-fed groups
by the end of the supplementation period, making it difﬁcult to
observe differences in DHA concentration. It is possible that rats fed
PL-DHA sources (PLC and FO+PLC groups) reached the steady-state
plateau more rapidly compared with FO-fed rats, consistent with
higher uptake of [U-3H]PC-DHA compared with [U-3H]TAG-DHA,
although this potential effect appears to be nulliﬁed by extending the
supplementation period to at least 4 weeks. In addition, the striatum
exhibited the lowest DHA accretion rate of any brain region analyzed,
but exhibited no differences in DHA concentration in response to
increasing PL-DHA intake. It is also possible that more DHA is entering
the brain in response to PL-DHA intake, but that it is not resulting inincreased accretion of DHA. For example, a previous study from our
group showed that rats fed ALA- or DHA-containing diets have similar
brain DHA concentrations despite DHA-fed animals having higher
brain DHA uptake rates [48]. In these cases, the turnover of brain DHA
may be increased; however, this requires investigation using in vivo
kineticmodeling [50]. A greater uptake of a tracer into brain lipids also
may not represent a major quantitative contribution to DHA
homeostasis and, as a result, may not translate into higher brain
DHA concentration. However, it is possible that the higher brain tracer
concentration in [U-3H]PC-DHA compared with [U-3H]TAG-DHA rats
indicates more rapid DHA uptake, which may be advantageous for
rapid delivery ofDHA in certain clinical settings [62]. Obese Zucker rats
fed krill oil, a PL-DHA source, have higher brain PL DHA compared to
ﬁsh oil-fed rats [63], possibly suggesting a selective effect of PL-DHA
on brain DHA in obese animals that may not occur in healthy animals.
The mechanism underlying the higher brain radioactivity in
[U-3H]PC-DHA compared with [U-3H]TAG-DHA rats is unclear, but
may involve differences in kinetics of serum radiotracer enrichment.
Slightly higher labeling of serum unesteriﬁed fatty acids, the serum
lipid pool that appears to be the main pool for brain DHA uptake
Fig. 4. DHA concentration of serum lipid fractions from rats fed diets supplementedwith OO, FO, PLC or FO+PLC expressed relative to olive oil-supplemented rats. DHA supplementation
increased serum lipid class DHA concentration in all DHA-supplemented groups relative to baseline. The source of DHAwas only a signiﬁcant factor in the DHA concentration of serum
unesteriﬁed fatty acids, in which PLC-supplemented rats had lower DHA than FO rats after 21 days of supplementation, but this difference disappeared at 28 days. FO+PLC had higher
serumTAGDHAat 28 days comparedwith FO. Data aremean±S.E.M. for seven to eight/group. Barswith a different superscriptwithin a timepoint are signiﬁcantly differentwithin that
time point by Tukey's post-hoc test following one-way ANOVA (Pb .05). Indicated P-values are derived from two-way ANOVA of time and DHA ester. OO: olive oil, FO: ﬁsh oil, PLC:
phospholipid concentrate, FO+PLC: ﬁsh oil + phospholipid concentrate.
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not in agreement with the lower brain tracer uptake in [U-3H]TAG-
DHA rats relative to [U-3H]PC-DHA. [U-3H]PC-DHA more effectively
labeled serum cholesteryl esters, consistent with preferential labeling
of HDL that has been observed for dietary PL previously [44,45]. It has
been proposed that small HDL particles can enter the brain through
the action of scavenger receptor Class B, Type I (SR-BI) on brain
capillary endothelial cells [64–66], suggesting a possible mechanism
for the higher brain tracer uptake in [U-3H]PC-DHA-gavaged rats
compared with [U-3H]TAG-DHA. SR-BI mediates cholesteryl ester
inﬂux in the liver [67], and as suchmaybe involved in brain cholesteryl
ester uptake in the brain aswell. BrainHDL uptake has previously beenproposed to be involved in brain DHAuptake [68], andHDL-associated
radioactivity is detected in mouse brain following injection of labeled
HDL particles [69]. Maintenance of whole-brain DHA concentration
does not require the low-density or very low density lipoprotein
receptors [70,71]; however, the role of HDL in brain DHA homeostasis
and targeted delivery of DHA to the brain is not clear.
The postprandial distribution of [U-3H]TAG-DHA and [U-3H]PC-
DHA radioactivity among the different serum lipid pools likely reﬂect
the differences in their digestion and absorption. Dietary TAG are
predominantly hydrolyzed by pancreatic lipase, which primarily
hydrolyzes fatty acids in the sn-1 and−3 positions of TAG, resulting
in two fatty acids and a sn-2-monoacylglycerol (MAG) [72]. These
Fig. 5. DHA concentration of tissues from rats fed diets supplemented with OO, FO, PLC and FO+PLC. All DHA-containing diets had higher tissue DHA compared with OO controls.
FO+PLC rats had higher heart DHA comparedwith FO-fed rats, andDHA concentrations in the rest of the tissues examinedwere not different amongDHA-supplementation groups. Data
are mean ± S.E.M. for seven to eight/group. Bars with a different superscript are signiﬁcantly different by Tukey's post-hoc test following one-way ANOVA (Pb .0.05). OO: olive oil, FO:
ﬁsh oil, PLC: phospholipid concentrate, FO+PLC: ﬁsh oil + phospholipid concentrate.
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for TAG synthesis for chylomicron secretion [73]. Therefore, at least
one third of the acyl-chain radioactivity of [U-3H]TAG-DHA is utilized
for TAG synthesis, and this is reﬂected in the radioactive enrichment of
serum TAG and its metabolites, MAG and DAG following [U-3H]TAG-
DHA ingestion. As the DHA in the [U-3H]TAG-DHA is in the sn-2
position, it is likely that the majority is absorbed as 2-DHA-MAG and
reesteriﬁed in the enterocyte. PL, on the other hand, is hydrolyzed by
activities of phospholipase A1 (pancreatic phospholipase A1[74],
secondary activity of pancreatic lipase in some species [75]) and A2
(pancreatic phospholipase A2[76], pancreatic lipase-related protein 2
[77]) into free fatty acids and sn-1/2-lysoPL. In the rat, approximately
half of the acyl chain moiety of ingested PC is absorbed as lyso-PC and
the other half as unesteriﬁed fatty acids, with the dominant LPC
species being 1-acyl-lysoPC [78], indicating that the major intestinal
phospholipase activity in rats is phospholipase A2. As the DHA in the
[U-3H]PC-DHA tracer was in the sn-2 position, it is likely that it was
absorbed in the unesteriﬁed form. [U-3H]PC-DHA appears to be apoorer substrate for enterocytic TAG synthesis as compared with
[U-3H]TAG-DHA, and the more effective labeling of serum cholesteryl
esters may result from the preferential incorporation of acyl moieties
from ingested PL into HDL observed previously [44,45]. [U-3H]PC-
DHA-gavaged rats also had a higher proportion of liver radioactivity in
the cholesteryl ester fraction, suggesting that secretion of radioactive
CE by the liver may have been higher in these rats compared to
[U-3H]TAG-DHA, although serum lecithin-cholesterol acyltransferase
may also be involved. It has been suggested that sn-1-lyso-2-DHA-PC
is themain serumDHA pool supplying the brain [30,61]; however, we
did not observe any differences in serum phospholipid labeling
between the two tracers, and fasting serum lysoPC DHA concentration
was similar between the three DHA-supplemented groups. The
presence of PL in PL-DHA may increase intestinal absorption of lipids
as biliary PC is required for intestinal TAG absorption [79] and
inclusion of PC in intestinal lipid infusion increases TAG absorption
[79–81]. However, similar whole-body DHA accretion rates between
FO, PLC and FO+PLC rats indicate that inclusion of PL-DHA in DHA
Table 2
Summary of DHA balance analysis
Olive oil Fish oil Phospholipid concentrate Fish oil + phospholipid concentrate
Whole-body DHA after 4 weeks (μmol) 68±5a 680±57b 797±62b 689±64b
Total dietary DHA intake (μmol) 146±20a 5402±1147b 5141±803b 6145±454b
Whole body DHA accretion (μmol) 23±5a 636±57b 752±62b 644±26b
Whole body DHA accretion rate (μmol/d) 0.8±0.2a 22.7±2.0b 26.8±2.2b 23.0±2.3b
Metabolic DHA consumption rate (μmol/d) 3±1a 168±16bc 158±9b 194±6c
% Apparent Dietary DHA β-oxidized 52±4a 87±1b 84±1b 88±1b
Total fecal DHA excretion (μmol) 0.6±0.1a 9.6±2.1b 23.0±1.6c 11.6±0.9b
% Dietary DHA excreted in feces 0.43±0.10ab 0.18±0.04a 0.46±0.04b 0.19±0.1a
Cortex DHA accretion rate (nmol/g/d) 15±18a 131±5b 128±4b 124±9b
Cerebellum DHA accretion rate (nmol/g/d) −31±9a 101±24b 95±11b 112±6b
Hippocampus DHA accretion rate (nmol/g/d) −9±25a 140±31b 121±13b 137±26b
Striatum DHA accretion rate (nmol/g/d) −31±105 34±6 36±9 54±17
Brainstem DHA accretion rate (nmol/g/d) −11±34a 101±10b 103±11b 115±15b
Remainder of brain DHA accretion rate (nmol/g/d) −29±10a 73±12b 67±13b 96±4b
Data are mean ± S.E.M. n=7–8/group. After 11-week n-3 PUFA deprivation, 8 rats were sacriﬁced to measure baseline DHA concentrations, and the difference after 4 weeks of
supplementationwith DHAor control dietwere determined tomeasure accretion rates. At baseline, whole-body DHAwas 45±3 μmol (n=8). Different superscript letters that indicate
means are signiﬁcantly different (Pb .05) determined by Tukey's post-hoc comparison following one-way ANOVA.
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the PLC-fed rats had the highest fecal DHA concentration (albeit less
than 0.5% of dietary DHA). However, a more direct measure of
intestinal DHA absorption is needed to deﬁnitively conclude this.
Importantly, the differences in postprandial serum lipid radioac-
tivity following gavage of [U-3H]TAG-DHA and [U-3H]PC-DHA did
not translate into clear differences in fasting serum lipid DHA
concentration in response to supplementing with a PL- compared
with TAG-DHA source for 4 weeks. Differences in serum lipid DHA
among the PL- and TAG-DHA-supplemented groups were time-point
speciﬁc, and PL- versus TAG-DHA sourcewas not a signiﬁcant factor for
any lipid class except for unesteriﬁed fatty acids. This suggests that
analysis of postprandial absorption kinetics will not match fasting
blood sampling following an intervention period. A recent randomized
controlled trial comparing krill oil (PL-EPA + DHA source) and ﬁsh oil
(TAG-EPA+DHA source) shows that krill oil had higher postprandial
serum phospholipid EPA+DHA, but that this trend was reversed
(albeit not statistically signiﬁcant) when examining plasma TAG
EPA+DHA [82]. Thus, the lipid pool examined can have signiﬁcant
effects on the conclusions of DHA bioavailability studies, indicating
that such studies should, in the absence of any clear rationale for
investigating a particular serum lipid class, examine bioavailability of
multiple serum lipid pools or of serum total lipids. Some of these
factors have been previously proposed to introduce signiﬁcant
heterogeneity in the assessment of DHA bioavailability [39].
The mixture of the FO and PLC DHA sources appeared to have a
positive effect on some measures of DHA concentration. The FO+PLC
group (in which approximately 30% of the total DHA was esteriﬁed to
phospholipids) had higher heart DHA and serum TAG DHA compared
with the FO group, consistent with higher heart DHA in krill oil- versus
ﬁsh oil-fed obese Zucker rats [83]. Interestingly, the higher heart DHA
in the FO+PLC rats relative to the FO rats did not correspond to
differences in heart radioactivity between [U-3H]PC-DHA and
[U-3H]TAG-DHA rats, suggesting that this effect is due to either the
speciﬁc mixture of PL- and TAG-DHA or the 4 weeks of supplemen-
tation. In the heart, DHA is also extensively incorporated into
cardiolipin [84] which is associated with modiﬁcations to mitochon-
drial enzyme function [85]. The acute absorption and tissue uptake
kinetics of various mixtures of various ratios PL-DHA and TAG-DHA
warrant investigation, as do the potential cardioprotective effects
speciﬁc to certain mixtures of PL-DHA and TAG-DHA.
The amount of tracer that appeared in the brain for both [U-3H]PC-
DHA and [U-3H]TAG-DHA tracers was low (less than 2×10−5% of the
dose) but is roughly consistent with previous studies (approximately
0.2% and 0.4% of dose in after 24 h in rat whole brain and 6 days inpiglet gray matter, respectively[42, 43]) considering differences in
sampling time postgavage, species, age of animals, analytical meth-
odologies and diet between the studies. This suggests that only a
minor fraction of ingested DHA targets the brain, regardless of the
form in which it is consumed. Themajor fate of PL-DHA and TAG-DHA
is oxidation, as evidenced by the high proportion of the DHA
consumed being β-oxidized (84–88%), consistent with previous
studies showing high DHA oxidation using the balance method to
examine DHA balance when fed as microalgal oil [58] or ethyl ester
[48], and the high proportion of label recovered in breath following
ingestion of [U-13C]DHA following ﬁsh oil supplementation [86].
Interestingly, the OO-fed rats had the lowest proportion of dietary
DHA oxidized (52%), indicating that DHA may be selectively retained
in these animals, consistent with previous work demonstrating
extended DHA half-life in brain following 15-week n-3 PUFA
deprivation [46] and lower breath recovery of [U-13C]DHA label in
individuals pre- comparedwith postﬁsh oil supplementation. A higher
rate of apparent metabolic DHA consumption (i.e., apparent β-
oxidation) was observed in rats fed the FO+PLC diet compared to
PLC, but this appears to have resulted from slightly higher intake of
DHA, as the percent of ingested DHA that was β-oxidized was not
different between groups. Krill-oil fed rats have recently been shown
to accrete a higher proportion of dietary DHA inwhole body compared
with ﬁsh oil-fed rats after 6 weeks of supplementation [87]. No
signiﬁcant differences in whole-body DHA accretionwere observed in
the present study of 4-week supplementation; however, PL-fed rats
had nonsigniﬁcantly higher whole-body DHA accretion compared to
FO and FO+PLC-fed rats. It is possible that longer duration of
supplementation is required to elicit differences in whole-body DHA
accretion between PL- and TAG-DHA.
There are several considerations regarding the interpretation of
this work. The isotope used was uniformly labeled, and as such, the
conclusions rendered from this study pertain to the entire sn-1,3-
palmitoyl-2-docosahexaenoylglycerol or 1-palmitoyl-2-docosahex-
aenoyl-sn-glycero-3-phosphocholine and not necessarily the DHA
contained within them. In [U-3H]TAG-DHA, the acyl chain radioactiv-
ity is one-third DHA and two-thirds palmitate, while in [U-3H]PC-DHA
it is one-half DHA and one-half palmitate. This likely does not affect
the serum lipid labeling of the tracers, as the appearance of DHA and
palmitate in serum lipids is very similar when provided orally as
unesteriﬁed fatty acids (TAGNNNEFANPLNDAGNCE for DHA [88] and
TAGNNNEFANCENPLNDAG for palmitate [27]). In addition, little
conversion of DHA to other fatty acids is likely to have occurred in
this study, as other studies have found low enrichment of other fatty
acidswith label provided as DHA22 h after oral administration in liver
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inmaternal baboons [90]. Similarly, appearance of orally administered
palmitate label as 18:0 and 16:1 is approximately 8% after 7 days in
humans [91] and has been below the detection limit 24 h after oral
dose in humans in one study [92], suggesting that the majority of
labeled palmitate ingested remains as labeled palmitate over the
course of this study. The higher brain radioactivity resulting from
[U-3H]PC-DHA compared with [U-3H]TAG-DHA gavage presently is
consistent with previous work in which only the sn-2 DHA is labeled
[42,43], indicating that this higher brain radioactivity in [U-3H]PC-
DHA rats was, at least in part, due to higher brain uptake of the
[3H]DHA moiety. Interestingly, baboon neonate brain takes up more
arachidonate when fed as sn-2-arachidonate-PC compared with sn-2-
arachidonate-TAG [93], suggesting that this effect is not limited to sn-
2-DHA-PC. The tracers were both dissolved in olive oil (virtually
entirely TAG) prior to gavage, and as such, the absorption matrix for
both TAG and PL tracers was TAG. This may have had some effects on
the absorption kinetics of the PL tracer. The DAG and cholesterol
fractions were collected together in the radiotracer gavage study, and
so the distribution of radioactivity between these two fractions is
unclear as carbon recycling into cholesterol could account for some of
the radioactivity.However, the appearanceof carbon in serumsaturated
fatty acids is low for DHA in rats over this time course (b3% of serum
label) [90], suggesting that cholesterol labeling via carbon recycling of
labeled DHA was likely low in this study. Another factor is the baseline
diet used in these studies, which is a low n-3 PUFA diet that has
previously been shown to increase brain DHA half-life [46] and hepatic
synthesis rate [94]. The present studies therefore represent n-3 PUFA
repletion on a very low n-3 PUFA background. However, the association
between low n-3 PUFA status and neurodegenerative [7–11] and
neuropsychiatric disorders [13–16] and cardiovascular mortality [95]
suggests that this experimental approach is relevant for determining
the relative efﬁcacy of different dietary forms of DHA on tissue DHA
uptake and concentration. Also, as the diet is essentially free of ALA
(b0.2% of dietary fatty acids), DHA synthesis from dietary ALA likely
does not contribute appreciably to changes in tissue and blood DHA
status throughout the study between DHA-supplemented groups [48].
The three DHA-supplemented groups were matched for DHA intake;
however, there were small differences in the EPA and 22:5n-3 dietary
content. Thesedifferences amounted to a range in total dietaryn-3PUFA
content between the three DHA-supplemented groups of only 3.31–
3.41% of total fatty acids.
This study conﬁrms greater brain uptake following an oral tracer
dose of DHA esteriﬁed to PL compared to TAG [42,43] but shows that
supplementing diets with a source of PL-DHA, TAG-DHA or a mixture
of both results in similar increases in brain DHA compared to a lown-3
diet. This suggests that the higher tracer uptake of PL-DHA compared
to TAG-DHA does not necessarily translate into higher brain DHA
concentration. In addition, signiﬁcant differenceswere observed in the
postprandial serum lipid radioactivity proﬁle following gavage of
[U-3H]PC-DHA compared with [U-3H]TAG-DHA, while only time
point-speciﬁc differences were observed in fasting serum DHA
concentrations during the 4-week PL-DHA versus TAG-DHA supple-
mentation study. This indicates that the study and sampling protocol
can have signiﬁcant effects on the conclusions obtained from studies
evaluating the effects of PL-DHA compared with TAG-DHA on blood
DHA levels. Overall, there appear to be differences in the digestion,
absorption and brain uptake of DHA esteriﬁed to PL compared to TAG;
however, these postprandial differences may not translate into
increased longer term blood and tissue DHA status following
supplementation with PL-DHA compared with TAG-DHA.
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